DRUG · Mapped RxNorm record
Dapagliflozin
Normalized identity: dapagliflozinView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
NCT02973477
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Glimepiride
Normalized identity: glimepirideView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedDapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Type2 Diabetesunresolved
Cardiovascular Diseasesunresolved
Interventions
DapagliflozinDRUG · verified · RxNorm: dapagliflozin
GlimepirideDRUG · verified · RxNorm: glimepiride
Sponsors & collaborators
University of Michiganlead sponsor
AstraZenecacollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02973477 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.